Trial Profile
Randomised Phase III Trial With Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotnib Followed of Capecitabine in Patients With Advanced Pancreatic Cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Erlotinib (Primary) ; Gemcitabine (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 24 Aug 2020 Translational results (n=243) published in the British Journal of Cancer
- 07 Jul 2012 The non-inferiority of treatment regimens on the primary endpoint 'Time-to-treatment-failure' has been met according to results published in Gut.
- 07 Jul 2012 Final results published in the Gut.